What patent(s) cover rolapitant in the US?
Rolapitant’s US patent coverage depends on the specific aspect you mean: the original drug “composition/product” patents, any method-of-use patents, and any later patents covering new formulations or specific clinical uses. Without the exact patent number(s) or the formulation/indication you care about, the only accurate way to answer “what patent(s) cover it in the US” is to look up rolapitant in the US patent database and identify the granted patents (and their assignees) for the relevant claims.
To get you the right, actionable list, share one of the following and I can narrow it down precisely:
- the exact drug name/formulation (e.g., brand name and whether it’s rolapitant tablets/capsules), or
- a patent number you’ve seen, or
- the indication you care about (e.g., CINV—chemotherapy-induced nausea and vomiting).
When does rolapitant’s US patent expire?
US “expiration” can mean different dates: the end of the last patent term, or later adjusted/extended terms (and sometimes exclusivity protections if a drug is approved under Hatch-Waxman or similar regimes). The effective date also varies by patent family (different filings can expire on different schedules).
If you provide the patent numbers (or the product label/brand), I can map each one to its expected US expiry/expiration date logic and explain which one controls exclusivity in practice.
Are there US patents listed in FDA Orange Book for rolapitant?
Often, the most practical answer for US market protection comes from the FDA’s Orange Book listing (which ties specific patents to a drug product and NDA/ANDA). That can show:
- which patents the manufacturer lists for the specific NDA product,
- the “regulatory” patent-expiration dates used for exclusivity planning.
If you share the NDA/brand name (or the link you’re looking at), I can explain how to interpret the Orange Book entries and what they imply for generic entry timing.
What are the common ways generic/competitor companies challenge rolapitant patents?
Generic challengers typically argue one or more of the following:
- the asserted patent(s) is invalid,
- the product does not infringe the asserted claims,
- or the claims are not enforceable as listed for the specific drug product.
Those disputes show up as patent litigation and can change “effective” entry timing even when patents still have term remaining.
If you tell me the company name (or any case citation), I can summarize the litigation posture using the specific public record.
Quick check: what do you mean by “Rolapitant patent us”?
Reply with one of these so I can give a precise US-focused answer:
1) “I want the Orange Book patent expiry for rolapitant (NDA/brand: ___)”
2) “I want the US patent numbers that cover rolapitant (assignee: ___)”
3) “I want the latest US litigation/case about rolapitant patents (case/citation: ___)”
Sources
I don’t have any specific patent number, Orange Book listing, or NDA/brand name to cite from in your message, so I can’t yet provide a sourced, accurate list or expiry date. Share the NDA/brand or a patent number and I’ll return a cited US-specific answer.